Publication

A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening

Koleva-Kolarova, R. G., De Jonge, C., Abu Hantash, M. K., Zhan, Z., Postema, E. J., Feenstra, T. L., Pijnappel, R. M., Greuter, M. J. & De Bock, G. H., Apr-2018, In : European Journal of Cancer. 92, Supp. 3, p. S11-S12 2 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Koleva-Kolarova, R. G., De Jonge, C., Abu Hantash, M. K., Zhan, Z., Postema, E. J., Feenstra, T. L., Pijnappel, R. M., Greuter, M. J., & De Bock, G. H. (2018). A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. European Journal of Cancer, 92(Supp. 3), S11-S12. https://doi.org/10.1016/S0959-8049(18)30274-0

Author

Koleva-Kolarova, R.G. ; De Jonge, C. ; Abu Hantash, M.K. ; Zhan, Z. ; Postema, E.J. ; Feenstra, T.L. ; Pijnappel, R.M. ; Greuter, M.J. ; De Bock, G.H. / A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. In: European Journal of Cancer. 2018 ; Vol. 92, No. Supp. 3. pp. S11-S12.

Harvard

Koleva-Kolarova, RG, De Jonge, C, Abu Hantash, MK, Zhan, Z, Postema, EJ, Feenstra, TL, Pijnappel, RM, Greuter, MJ & De Bock, GH 2018, 'A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening', European Journal of Cancer, vol. 92, no. Supp. 3, pp. S11-S12. https://doi.org/10.1016/S0959-8049(18)30274-0

Standard

A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. / Koleva-Kolarova, R.G.; De Jonge, C.; Abu Hantash, M.K.; Zhan, Z.; Postema, E.J.; Feenstra, T.L.; Pijnappel, R.M.; Greuter, M.J.; De Bock, G.H.

In: European Journal of Cancer, Vol. 92, No. Supp. 3, 04.2018, p. S11-S12.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Koleva-Kolarova RG, De Jonge C, Abu Hantash MK, Zhan Z, Postema EJ, Feenstra TL et al. A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. European Journal of Cancer. 2018 Apr;92(Supp. 3):S11-S12. https://doi.org/10.1016/S0959-8049(18)30274-0


BibTeX

@article{2df775b8af49484ab2a98ace5cfa950c,
title = "A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening",
abstract = "Background: Increased breast cancer incidence between 45 and 50 years of age requires reconsideration of the current starting age of routine mammography. Our aim was to evaluate the quantitative benefits, harms, and cost-effectiveness of lowering the starting age of breast cancer screening in the Dutch general population. Methods: Economic modelling with a lifelong perspective compared biennial screening 48-74 and 46-74 to the current Dutch screening program (50-74). Tumour deaths prevented, years of life saved (YOLS), false positives, radiation-induced tumours, costs and incremental costseffectiveness ratios (ICERs) were evaluated. Results: Starting the screening at 48 vs. 50 led to an increase in: the number of small screen detected tumours (4.0%), tumour deaths prevented (5.6%), false positives (9.2%), YOLS (5.6%), radiation-induced tumours (14.7%), and costs (4.1%). Starting the screening at 46 vs. 48 increased the number of small screen detected tumours (3.3%), tumour deaths prevented (4.2%), false positives (8.8%), YOLS (3.7%), radiation-induced tumours (15.2%), and costs (4.0%). The ICER was €5,600/YOLS for 48-74 scenario and €5,600/YOLS for 46-74. Conclusions: Women could benefit from lowering the starting age of screening as more breast cancer deaths will be averted. Starting regular breast cancer screening earlier is also cost-effective. As the number of additional expected harms is relatively small in both alternative scenarios and the difference in ICERs is not large, introducing two additional screening rounds is justifiable.",
keywords = "adult, breast cancer, cancer screening, conference abstract, cost effectiveness analysis, death, false positive result, female, human, population, radiation induced neoplasm",
author = "R.G. Koleva-Kolarova and {De Jonge}, C. and {Abu Hantash}, M.K. and Z. Zhan and E.J. Postema and T.L. Feenstra and R.M. Pijnappel and M.J. Greuter and {De Bock}, G.H.",
year = "2018",
month = apr,
doi = "10.1016/S0959-8049(18)30274-0",
language = "English",
volume = "92",
pages = "S11--S12",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",
number = "Supp. 3",

}

RIS

TY - JOUR

T1 - A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening

AU - Koleva-Kolarova, R.G.

AU - De Jonge, C.

AU - Abu Hantash, M.K.

AU - Zhan, Z.

AU - Postema, E.J.

AU - Feenstra, T.L.

AU - Pijnappel, R.M.

AU - Greuter, M.J.

AU - De Bock, G.H.

PY - 2018/4

Y1 - 2018/4

N2 - Background: Increased breast cancer incidence between 45 and 50 years of age requires reconsideration of the current starting age of routine mammography. Our aim was to evaluate the quantitative benefits, harms, and cost-effectiveness of lowering the starting age of breast cancer screening in the Dutch general population. Methods: Economic modelling with a lifelong perspective compared biennial screening 48-74 and 46-74 to the current Dutch screening program (50-74). Tumour deaths prevented, years of life saved (YOLS), false positives, radiation-induced tumours, costs and incremental costseffectiveness ratios (ICERs) were evaluated. Results: Starting the screening at 48 vs. 50 led to an increase in: the number of small screen detected tumours (4.0%), tumour deaths prevented (5.6%), false positives (9.2%), YOLS (5.6%), radiation-induced tumours (14.7%), and costs (4.1%). Starting the screening at 46 vs. 48 increased the number of small screen detected tumours (3.3%), tumour deaths prevented (4.2%), false positives (8.8%), YOLS (3.7%), radiation-induced tumours (15.2%), and costs (4.0%). The ICER was €5,600/YOLS for 48-74 scenario and €5,600/YOLS for 46-74. Conclusions: Women could benefit from lowering the starting age of screening as more breast cancer deaths will be averted. Starting regular breast cancer screening earlier is also cost-effective. As the number of additional expected harms is relatively small in both alternative scenarios and the difference in ICERs is not large, introducing two additional screening rounds is justifiable.

AB - Background: Increased breast cancer incidence between 45 and 50 years of age requires reconsideration of the current starting age of routine mammography. Our aim was to evaluate the quantitative benefits, harms, and cost-effectiveness of lowering the starting age of breast cancer screening in the Dutch general population. Methods: Economic modelling with a lifelong perspective compared biennial screening 48-74 and 46-74 to the current Dutch screening program (50-74). Tumour deaths prevented, years of life saved (YOLS), false positives, radiation-induced tumours, costs and incremental costseffectiveness ratios (ICERs) were evaluated. Results: Starting the screening at 48 vs. 50 led to an increase in: the number of small screen detected tumours (4.0%), tumour deaths prevented (5.6%), false positives (9.2%), YOLS (5.6%), radiation-induced tumours (14.7%), and costs (4.1%). Starting the screening at 46 vs. 48 increased the number of small screen detected tumours (3.3%), tumour deaths prevented (4.2%), false positives (8.8%), YOLS (3.7%), radiation-induced tumours (15.2%), and costs (4.0%). The ICER was €5,600/YOLS for 48-74 scenario and €5,600/YOLS for 46-74. Conclusions: Women could benefit from lowering the starting age of screening as more breast cancer deaths will be averted. Starting regular breast cancer screening earlier is also cost-effective. As the number of additional expected harms is relatively small in both alternative scenarios and the difference in ICERs is not large, introducing two additional screening rounds is justifiable.

KW - adult

KW - breast cancer

KW - cancer screening

KW - conference abstract

KW - cost effectiveness analysis

KW - death

KW - false positive result

KW - female

KW - human

KW - population

KW - radiation induced neoplasm

U2 - 10.1016/S0959-8049(18)30274-0

DO - 10.1016/S0959-8049(18)30274-0

M3 - Article

VL - 92

SP - S11-S12

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - Supp. 3

ER -

ID: 75256041